LITS (Lite Strategy) Beta: 0.4194 (As of Jun. 25, 2026)


LITS Lite Strategy Inc LITS
22 GF Score
Price $0.84
! 2 Warning Signs
View Full Analysis

What is Lite Strategy Beta?

Lite Strategy LITS -3.50% 22 Beta is 0.4194 as of Jun. 25, 2026. GuruFocus rates LITS with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Lite Strategy's Beta is 0.4194.


Lite Strategy  (NAS:LITS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Lite Strategy Beta Related Terms


Lite Strategy Beta Historical Data

* Premium members only.

The historical data trend for Lite Strategy's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lite Strategy Beta Chart

Lite Strategy Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.56 1.05 -0.05 0.05 0.74

Lite Strategy Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.74 0.88 0.80 0.37

LITS vs DARE, ALGS, TVGN: Beta Comparison

For the Biotechnology subindustry, Lite Strategy's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lite Strategy Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lite Strategy's Beta distribution charts can be found below:

* The bar in red indicates where Lite Strategy's Beta falls into.


LITS
22GF Score
Lite Strategy Inc LITS
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lite Strategy Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.4194 mean?
Lite Strategy (LITS) has a Beta of 0.4194 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lite Strategy and its competitors.
Is Lite Strategy's Beta too high?
Lite Strategy's current Beta is 0.4194. Overall, Lite Strategy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Lite Strategy's Beta compare to DARE and ALGS?
Lite Strategy's Beta of 0.4194 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lite Strategy and its competitors. Lite Strategy's current Beta is 0.4194. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lite Strategy stock overvalued right now?
Lite Strategy (LITS) has a current Beta of 0.4194. The current Beta is 0.4194. Lite Strategy's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Lite Strategy (LITS), the current Beta is 0.4194 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lite Strategy Business Description

Other Exchanges 0JW9:UK
Address 9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
22GF Score

Get the complete analysis for LITS

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.84
Price